Literature DB >> 34352256

Classification, outcomes, and management of misdeployed stents during EUS-guided gastroenterostomy.

Bachir Ghandour1, Michael Bejjani1, Shayan S Irani2, Reem Z Sharaiha3, Thomas E Kowalski4, Douglas K Pleskow5, Khanh Do-Cong Pham6, Andrea A Anderloni7, Belen Martinez-Moreno8, Harshit S Khara9, Lionel S D'Souza10, Michael Lajin11, Bharat Paranandi12, Jose Carlos Subtil13, Carlo Fabbri14, Tobias Weber15, Marc Barthet16, Mouen A Khashab1.   

Abstract

BACKGROUND AND AIMS: Stent misdeployment (SM) has hindered the dissemination of EUS-guided gastroenterostomy (EUS-GE) for gastric outlet obstruction (GOO) management. We aimed to provide a classification system for SM during EUS-GE and study clinical outcomes and management accordingly.
METHODS: This is a retrospective study involving 16 tertiary care centers (8 in the United States, 8 in Europe) from March 2015 to December 2020. Patients who developed SM during EUS-GE for GOO were included. We propose classifying SM into 4 types. The primary outcome was rate and severity of SM (per American Society for Gastrointestinal Endoscopy lexicon), whereas secondary outcomes were clinical outcomes and management of dislodgement according to the SM classification type, in addition to salvage management of GOO after SM.
RESULTS: From 467 EUS-GEs performed for GOO during the study period, SM occurred in 46 patients (9.85%). Most SMs (73.2%) occurred during the first 13 EUS-GE cases by the performing operators. SM was graded as mild (n = 28, 60.9%), moderate (n = 11, 23.9%), severe (n = 6, 13.0%), or fatal (n = 1, 2.2%), with 5 patients (10.9%) requiring surgical intervention. Type I SM was the most common (n = 29, 63.1%), followed by type II (n = 14, 30.4%), type IV (n = 2, 4.3%), and type III (n = 1, 2.2%). Type I SM was more frequently rated as mild compared with type II SM (75.9% vs 42.9%, P = .04) despite an equivalent rate of surgical repair (10.3% vs 7.1%, P = .7). Overall, 4 patients (8.7%) required an intensive care unit stay (median, 2.5 days). The median length of stay was 4 days after SM.
CONCLUSIONS: Although SM is not infrequent during EUS-GE, most are type I, mild/moderate in severity, and can be managed endoscopically with a surgical intervention rate of approximately 11%.
Copyright © 2022 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34352256     DOI: 10.1016/j.gie.2021.07.023

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  5 in total

1.  EUS-guided gastroenteric anastomosis: A first-line approach for gastric outlet obstruction?

Authors:  Daryl Ramai; Antonio Facciorusso; Stefano Francesco Crinò; Douglas G Adler
Journal:  Endosc Ultrasound       Date:  2021 Nov-Dec       Impact factor: 5.628

2.  EUS-GE in ascites: Swim carefully lest your patient drowns!

Authors:  Basha Jahangeer; Sundeep Lakhtakia; Raghavendra Yarlagadda; Zaheer Nabi; Nageshwar Reddy
Journal:  Endosc Int Open       Date:  2022-04-14

3.  EUS-guided gastrojejunostomy for management of malignant gastric outlet obstruction in a patient with Roux-en-Y anatomy.

Authors:  Charlotte Campbell; Rishi Pawa
Journal:  VideoGIE       Date:  2022-07-21

Review 4.  Endoscopic ultrasound-guided biliary drainage and gastrointestinal anastomoses: the journey from promising innovations to standard of care.

Authors:  Giuseppe Vanella; Giuseppe Dell'Anna; Michiel Bronswijk; Roy L J van Wanrooij; Gianenrico Rizzatti; Paraskevas Gkolfakis; Alberto Larghi; Schalk van der Merwe; Paolo Giorgio Arcidiacono
Journal:  Ann Gastroenterol       Date:  2022-07-15

Review 5.  Hybrid gastroenterostomy using a lumen-apposing metal stent: a case report focusing on misdeployment and systematic review of the current literature.

Authors:  Carlo Fabbri; Cecilia Binda; Paola Fugazzola; Monica Sbrancia; Matteo Tomasoni; Chiara Coluccio; Carlo Felix Maria Jung; Enrico Prosperi; Vanni Agnoletti; Luca Ansaloni
Journal:  World J Emerg Surg       Date:  2022-01-22       Impact factor: 5.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.